YPSN Ypsomed Holding AG
Ypsomed Holding AG, together with its subsidiaries, develops, manufactures, and sells injection and infusion systems for safe and simple self-medication in Switzerland, Europe, North America, and internationally. The company offers various injection systems, such as pen injectors, auto-injectors, and wearable injectors, as well as other related services. It offers contract manufacturing of infusion sets and reservoirs. The company markets its products to hospitals, doctors, pharmacies and patients via subsidiaries and distributors. Ypsomed Holding AG was founded in 1984 and is headquartered in Burgdorf, Switzerland.…
Industry Peers
Medical Instruments & SuppliesKey Statistics
About Ypsomed Holding (SWX: YPSN)
›
Ypsomed Holding (SWX: YPSN) is listed on the SIX Swiss Exchange, where its shares trade in CHF. It belongs to the Medical Instruments & Supplies industry, part of the Healthcare sector, and reports about 2,025 employees.
The shares were at 440.60 CHF on 19 November 2026, up 36.0% over 52 weeks. Its 52-week range is 260.50 CHF to 447.80 CHF: the price is 1.6% below the high and 69.1% above the low.
At a market capitalisation of 5.79B CHF, it trades at 34.9 times trailing earnings and 29.0 times forward earnings. The median trailing P/E of its 19 largest Medical Instruments & Supplies peers is 49.2, a discount of 29% for YPSN. It pays a dividend yielding 1.00% (it pays out 35% of its earnings), against a median of 0.93% among the dividend payers in that peer group.
Ypsomed Holding reports return on equity of 29.7%, an operating margin of 31.0% and revenue down 12.4% year over year.
Its debt exceeds its cash by 300.14M CHF, a debt-to-equity ratio of 0.35. Its Piotroski F-score is 8 out of 9, a strong reading of its financial health. 14 analysts cover the stock, with an average rating of Buy; their mean price target of 422.57 CHF is 4.1% below the current price. The next earnings report is expected on 19 May 2027.